CA2452364A1 - Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins - Google Patents

Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins Download PDF

Info

Publication number
CA2452364A1
CA2452364A1 CA002452364A CA2452364A CA2452364A1 CA 2452364 A1 CA2452364 A1 CA 2452364A1 CA 002452364 A CA002452364 A CA 002452364A CA 2452364 A CA2452364 A CA 2452364A CA 2452364 A1 CA2452364 A1 CA 2452364A1
Authority
CA
Canada
Prior art keywords
interferon
polypeptide
composition according
interferon gamma
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002452364A
Other languages
English (en)
French (fr)
Inventor
Jorn Drustrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen ApS
Maxygen Holdings Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2452364A1 publication Critical patent/CA2452364A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002452364A 2001-06-29 2002-06-28 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins Abandoned CA2452364A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200101040 2001-06-29
DKPA200101040 2001-06-29
DKPA200101277 2001-08-30
DKPA200101277 2001-08-30
DKPA200200257 2002-02-19
DKPA200200257 2002-02-19
PCT/DK2002/000444 WO2003002152A2 (en) 2001-06-29 2002-06-28 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins

Publications (1)

Publication Number Publication Date
CA2452364A1 true CA2452364A1 (en) 2003-01-09

Family

ID=27222516

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002452364A Abandoned CA2452364A1 (en) 2001-06-29 2002-06-28 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins

Country Status (7)

Country Link
EP (1) EP1414498A2 (enExample)
JP (1) JP2004522803A (enExample)
CN (1) CN1522159A (enExample)
CA (1) CA2452364A1 (enExample)
MX (1) MXPA03011793A (enExample)
RU (1) RU2004102500A (enExample)
WO (1) WO2003002152A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10012064B2 (en) 2015-04-09 2018-07-03 Highlands Natural Resources, Plc Gas diverter for well and reservoir stimulation
US10344204B2 (en) 2015-04-09 2019-07-09 Diversion Technologies, LLC Gas diverter for well and reservoir stimulation
US10982520B2 (en) 2016-04-27 2021-04-20 Highland Natural Resources, PLC Gas diverter for well and reservoir stimulation

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
RS20050502A (sr) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
US7846427B2 (en) 2003-12-11 2010-12-07 Ares Trading S.A. Stabilized interferon liquid formulations
BRPI0510527A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
US20070212306A1 (en) * 2004-06-07 2007-09-13 Quay Steven C Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
WO2007101949A2 (fr) * 2006-03-08 2007-09-13 Biomethodes Variants de l'interferon- gamma humain (infgamma)
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
MX2009011619A (es) * 2007-04-27 2010-01-18 Cydex Pharmaceuticals Inc Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
ES2387236T3 (es) 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
AR074357A1 (es) * 2008-11-17 2011-01-12 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro
KR101743591B1 (ko) 2009-05-13 2017-06-20 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
RU2482871C2 (ru) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Композиция для лечения вирусных заболеваний животных
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP7105200B2 (ja) * 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
CA3108066A1 (en) * 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
CN111358938B (zh) * 2020-03-30 2023-08-11 温州肯恩大学(Wenzhou-KeanUniversity) 人干扰素-ε与干扰素-γ组合药及用途
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6133248A (en) * 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10012064B2 (en) 2015-04-09 2018-07-03 Highlands Natural Resources, Plc Gas diverter for well and reservoir stimulation
US10344204B2 (en) 2015-04-09 2019-07-09 Diversion Technologies, LLC Gas diverter for well and reservoir stimulation
US10385258B2 (en) 2015-04-09 2019-08-20 Highlands Natural Resources, Plc Gas diverter for well and reservoir stimulation
US10385257B2 (en) 2015-04-09 2019-08-20 Highands Natural Resources, PLC Gas diverter for well and reservoir stimulation
US10982520B2 (en) 2016-04-27 2021-04-20 Highland Natural Resources, PLC Gas diverter for well and reservoir stimulation

Also Published As

Publication number Publication date
EP1414498A2 (en) 2004-05-06
CN1522159A (zh) 2004-08-18
JP2004522803A (ja) 2004-07-29
MXPA03011793A (es) 2004-04-02
RU2004102500A (ru) 2005-04-10
WO2003002152A3 (en) 2003-05-01
WO2003002152A2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
US20030138403A1 (en) Interferon formulations
CA2452364A1 (en) Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
EP1366075B1 (en) New interferon beta-like molecules
IL149267A (en) Couplings of interferon gamma
US7419805B2 (en) Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression
WO2001015736A2 (en) Interferon-beta conjugates
US7431921B2 (en) Interferon beta-like molecules
KR20030094336A (ko) 인터페론 감마 폴리펩티드 변이체
US7524931B2 (en) Full-length interferon gamma polypeptide variants
US7390638B2 (en) S99T C-11 Truncated polynucleotides encoding interferon gamma polypeptide variants
AU2002319109A1 (en) Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
WO2002036628A2 (en) New multimeric interferon beta polypeptides
AU2002252971B2 (en) Interferon gamma polypeptide variants
ZA200303964B (en) New interferon beta-like molecules.
AU2002235727A1 (en) New interferon beta-like molecules
ZA200200337B (en) New interferon beta-like molecules.
ZA200308376B (en) Interferon gamma polypeptide variants.
AU2002252971A1 (en) Interferon gamma polypeptide variants
CZ20033016A3 (cs) Varianty polpeptidu interferonu gamma

Legal Events

Date Code Title Description
FZDE Dead